CDC reports the highest measles case counts in 2026 YTD.

The U.S. is reporting its highest measles case counts in decades, and the real story for diagnostics leaders is how this resurgence is reshaping competitive dynamics across MMRV serology and molecular testing. Core lab giants like Roche, Abbott, Siemens, Beckman, and bioMérieux continue to dominate immune status and IgG/IgM testing through massive installed bases, while specialty players such as EUROIMMUN and Bio-Rad are gaining traction with high-sensitivity and multiplex MMRV panels. Emerging platforms — including Dynex’s SmartPLEX technology — are quietly positioning for share in mid-volume labs.

As vaccine-preventable diseases climb, competitive positioning will shift fast. CDC measles reports the highest measles case counts. • Record U.S. measles burden: As of July 30, 2026, the U.S. has reported 2,371 confirmed measles cases, already exceeding the 2,289 cases in 2025, which CDC had flagged as the second highest annual count in 25 years. • Signal for diagnostics: This sustained, multi-year surge in a vaccine-preventable disease materially increases demand for measles (and broader MMRV) testing in both public health and clinical lab settings. U.S. laboratories are experiencing a clear and measurable increase in demand for measles-related testing, and this rise is directly tied to the surge in national measles cases. Two independent, peer-reviewed sources confirm this trend. Evidence of Increased Measles (MMRV-related) Testing Demand • A large U.S. commercial laboratory (Labcorp/Monogram Biosciences) reported sharp increases in measles IgM, IgG, and PCR test orders beginning January 2025, with IgM volumes already rising steadily since mid 2024. • A national reference laboratory validated and deployed a new dual-target measles PCR assay specifically because 2025 measles cases reached their highest level since elimination in 2000, requiring expanded testing capacity. Taken together, these data show a sustained, multi-year rise in measles testing volumes across serology and molecular methods — a direct proxy for increased MMRV-related diagnostic demand.

What This Means for MMRV Testing Demand More Broadly While the published data focus on measles, the operational reality is that MMRV testing demand rises in parallel because: • Immune status panels (MMR or MMRV IgG) are ordered when measles exposure risk increases. • Clinicians often pair measles testing with mumps/rubella serology to assess immunity gaps. • Public health labs expand varicella testing during exanthem outbreaks to differentiate cases. Increased measles activity reliably drives higher MMRV testing volumes across U.S. labs.

Strategic Implication for Diagnostics Manufacturers The surge in testing is already influencing: • Higher utilization of core lab immunoassay platforms (Roche, Abbott, Siemens, Beckman, bioMérieux). • Growing interest in multiplex immune status panels (Bio Rad BioPlex, Dynex SmartPLEX). • Expanded molecular testing capacity (Hologic Panther Fusion, Roche cobas, Abbott Alinity m). This shift is reshaping competitive positioning in the MMRV testing market.